IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
Critical role for TRIM28 and HP1β/γ in the epigenetic control of T cell metabolic reprograming and effector differentiation.Proc. Natl. Acad. Sci. U.S.A. 2019-12-24;116(51):25839-25849.
Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia.Cancers (Basel) 2019-12-21;11(12).
Genetic characterization of ABT-199 sensitivity in human AML.Leukemia 2019-12-19;34(1):63-74.
Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1.Sci Rep 2019-12-09;9(1):17620.
Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation.Proc. Natl. Acad. Sci. U.S.A. 2019-12-07;116(48):24056-24065.
Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.Genes Chromosomes Cancer 2019-12-03;59(2):125-130.
Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.Appl Health Econ Health Policy 2019-12-02;17(6):827-839.
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.Leukemia 2019-11-29;33(12):2830-2841.
Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.Ann. Surg. Oncol. 2019-11-20;26(13):4337-4345.